Product Description
Verapamil is used to treat high blood pressure and to control angina (chest pain). The immediate-release tablets are also used alone or with other medications to prevent and treat irregular heartbeats. Verapamil is in a class of medications called calcium-channel blockers. It works by relaxing the blood vessels so the heart does not have to pump as hard.
Mechanisms of Action: Calcium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Abbott Laboratories
Company Location: ABBOTT PARK IL 60064-3500
Company CEO: Robert B. Ford
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Sweden, United States
Active Clinical Trial Count: 8
Highest Development Phases
Phase 3: Type 1 Diabetes
Phase 2: Cardiomyopathy, Hypertrophic|Panic Disorder
Phase 1: Cardiomyopathies|Chronic Obstructive Pulmonary Disease|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| HB-PD-002 | P2 |
Not yet recruiting |
Panic Disorder |
2026-01-01 |
|
| TEMPO II | P2 |
Active, not recruiting |
Cardiomyopathy, Hypertrophic |
2025-04-11 |
|
| HRS-1893-102 | P1 |
Completed |
Cardiomyopathy, Hypertrophic|Cardiomyopathies |
2024-05-20 |
|
| EP395-004 | P1 |
Completed |
Chronic Obstructive Pulmonary Disease |
2024-01-02 |
53% |
| EP395-004 | P1 |
Completed |
Chronic Obstructive Pulmonary Disease |
2024-01-02 |
53% |